Elicio Therapeutics ELTX Institutional Ownership

Updated Oct 10, 2026

Elicio Therapeutics, Inc. (NASDAQ:ELTX) appeared in the 13F filings of 49 institutional investors for the quarter ended June 30, 2026.

• Together they owned 17.91% of the outstanding stock in Q2 2026, up from 14.16% a quarter earlier.
• Total holdings of Elicio Therapeutics shares rose 48.60% from Q1 2026, and the number of holders rose 145.00% from Q2 2025.
• Of these 49 holders, 39 added to their positions, 3 reduced their stakes and 7 left their positions unchanged.
• The aggregate institutional position in Elicio Therapeutics was 3.92Mn shares at the end of Q2 2026, up 1.28Mn from the prior quarter and up 2.47Mn from a year earlier.
• As of June 30, 2026, the biggest holder of Elicio Therapeutics was Knoll Capital Management, LLC with 1.21Mn shares, or 5.53% of shares outstanding.
• The biggest increases in ELTX positions during Q2 2026 came from BlackRock, Inc. (+715.41K shares), Knoll Capital Management, LLC (+581.04K shares), Geode Capital Management, LLC (+176.19K shares), State Street Corp (+128.8K shares) and Northern Trust Corp (+70.43K shares).
• The largest position reductions in ELTX for Q2 2026 were by Morgan Stanley (-6.86K shares), BNP Paribas Financial Markets (-4.27K shares) and Summit Financial, LLC (-5 shares).
• Business Quant data shows the 10 biggest positions in Elicio Therapeutics as of Q2 2026 were held by Knoll Capital Management, LLC (1.21Mn shares), BlackRock, Inc. (766K shares), Vanguard Capital Management LLC (572.15K shares), Geode Capital Management, LLC (311.35K shares), State Street Corp (179.42K shares), Northern Trust Corp (130.16K shares), Ikarian Capital, LLC (100K shares), Vanguard Portfolio Management LLC (88.91K shares), Vanguard Fiduciary Trust Co (88.06K shares) and AllianceBernstein L.P. (81.28K shares).